News

India’s Growth Surprise Seen Adding to Troubles for Stock Market

(Bloomberg) -- Follow Bloomberg India on WhatsApp for exclusive content and analysis on what billionaires, businesses and markets are doing. Sign up here.Most Read from BloombergRiyadh Metro Partially Opens in Bid to Ease City’s Traffic JamsIn Traffic-Weary Toronto, a Battle Breaks Out Over Bike LanesA hiccup in India’s world-beating economic growth may exacerbate near-term weakness in stocks, according to strategists. The economy expanded at the slowest pace in almost two years in the September

JPMorgan Traders’ Math Places S&P 500 Near 6,300 By Month’s End

(Bloomberg) -- Even after the strongest rally since the early days of the dot-com boom, the S&P 500 Index still has room to push higher through the end of the year, according to JPMorgan Chase & Co.’s trading desk.Most Read from BloombergRiyadh Metro Partially Opens in Bid to Ease City’s Traffic JamsAs Wars Rage, Cities Face a Dark New Era of Urban DestructionDerivatives analysts at the bank say the most popular options trades are wagering the US equity benchmark will hit 6,200 to 6,300 this mon

Why Is Senti Biosciences Stock Surging Over 400% On Monday?

Senti Biosciences, Inc. (NASDAQ:SNTI) stock is skyrocketing on Monday, with a strong session volume of 73.4 million compared to an average volume of 17.81 thousand, as per data from Benzinga Pro. The company reported initial clinical data from a Phase 1 trial of SENTI-202, a potential first-in-class Logic Gated off-the-shelf chimeric antigen receptor natural killer (CAR-NK) investigational cell therapy, for relapsed/refractory hematologic malignancies including acute myeloid leukemia. SENTI-202